Últimas noticias sobre P3 Health Partners (NASDAQ:PIII) Bolsa

P3 Health Partners

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners Inc

Can a cannabis brand go from a garage startup to an acquisition by a multi-state operator in a few years? LEVIA did exactly that. What began as an experiment in cannabis tinctures, brewed above a Massachusetts garage, quickly became one of the state&#8217;s top-selling cannabis beverage brands—selling out before their products even hit the shelves.
For cannabis investors, the LEVIA story isn't just a tale of entrepreneurial grit; it's a roadmap to success in a rapidly growing sector. By focusing on a unique, effects-based product and seizing an untapped opportunity in the market, founders Kristin and Eric Rogers scaled their startup into a high-demand brand that caught the attention of AYR Wellness.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h2 class="wp-block-heading">Can Cannabis Be More Than Smoking?</h2>
Before <a href="https://levia.buzz/products/cannabis-infused-seltzer/">LEVIA</a> was a household name in the Massachusetts cannabis scene, it was a small venture operating out of the Rogers&#8217; garage. Kristin, a substance abuse therapist and Eric, a brand marketer, both saw the potential for cannabis to change lives, particularly as an alternative to harmful substances like alcohol and opioids. 
Their journey began with a simple question: How do we create a cannabis product that doesn't require smoking?
&#8220;My husband started making tinctures using medicinal cannabis, and we realized very quickly this was a thing,&#8221; Kristin said. &#8220;We also picked strains. Eric found medicinal strains that were very specific on what their purpose was.&#8221;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="680" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164644/KRogers-Headshot-3.15.24-680x1024.jpg" alt="" class="wp-image-601646" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164644/KRogers-Headshot-3.15.24-680x1024.jpg 680w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164644/KRogers-Headshot-3.15.24-199x300.jpg 199w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164644/KRogers-Headshot-3.15.24.jpg 717w" sizes="(max-width: 680px) 100vw, 680px" /><figcaption class="wp-element-caption">Kristin Rogers &#8211; LEVIA&#8217;s co-founder. </figcaption></figure>
Their mission was clear: to create consistent, reliable cannabis products that mirrored the predictability of alcohol consumption. LEVIA's first tinctures were alcohol-based, but, they wanted to move away from alcohol-based products.
&#8220;We wanted to help people use cannabis without having to smoke it, and at the same time, we wanted to provide something that could compete with alcohol,&#8221; Kristin told Benzinga. &#8220;The idea was to create a product where you know how you're going to feel, just like when you drink a glass of wine.&#8221;
<h3 class="wp-block-heading">Enter The Beverage Market: Scaling The Dream</h3>
As LEVIA grew, so did the need for a larger, more sophisticated operation. They raised money &#8220;on hopes and dreams&#8221; and managed to retrofit a brewery in Georgetown, <a href="https://www.benzinga.com/topic/massachusetts-cannabis">Massachusetts</a> where they could produce their products on a much larger scale.
Their hard work paid off. LEVIA&#8217;s cannabis seltzers, known for their fast onset, zero calories and zero sugar, quickly captured the attention of consumers. The brand introduced three signature lines—Achieve, Celebrate and Dream—each tailored to specific consumer needs. &#8220;We realized early on that no one was doing effects-based drinks,&#8221; Kristin says. 
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/40886620/how-this-former-dea-consultant-is-making-craft-cannabis-profitable-in-new-jersey-a-dirt-y-little"> How This Former DEA Consultant Is Making Craft Cannabis Profitable In New Jersey: A &#8216;Dirt-y&#8217; Little Secret</a>
<h3 class="wp-block-heading">Building A Brand: Crafting The Perfect Lineup</h3>
When it came time to brand their products, Kristin and Eric honed in on a clean, apothecary-style look, something that conveyed quality and care. But the branding was only one piece of the puzzle. LEVIA's real breakthrough came in narrowing its product line to three drinks. The rationale? Simplicity, clarity and <a href="https://www.benzinga.com/topic/cannabis-marketing">targeting a broad range of consumer needs. </a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="884" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164811/ice3.jpg" alt="" class="wp-image-601649" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164811/ice3.jpg 884w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164811/ice3-259x300.jpg 259w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164811/ice3-768x890.jpg 768w" sizes="(max-width: 884px) 100vw, 884px" /><figcaption class="wp-element-caption">Courtesy of LEVIA</figcaption></figure>
"We started by picking specific strains but quickly realized we couldn't guarantee the same strain every time. So we focused on what most people want to feel." Kristin said.
<h3 class="wp-block-heading">Clean Extraction: LEVIA's Full-Spectrum Advantage</h3>
LEVIA's success is rooted in its full-spectrum products, which contain all the naturally occurring compounds from the cannabis plant—<a href="https://www.benzinga.com/general/biotech/23/10/35300227/from-cbn-cbg-to-thcv-consumer-centric-brands-embrace-rare-cannabinoids-for-differentiation">THC, CBD, CBG and terpenes</a>—creating an enhanced &#8220;entourage effect&#8221; for a more balanced experience.
Using CO2 extraction, one of the cleanest methods, LEVIA ensures its products are potent and pure. This process preserves the plant's natural compounds without leaving harmful solvents. As Kristin puts it, "We're chasing the closest thing we can get to smoking, but without the smoke."
<h2 class="wp-block-heading">It's A Match!&nbsp;</h2>
Within just six months of launching, LEVIA's success was undeniable. The brand's beverages were selling out before they even hit the shelves. This rapid growth caught the attention of larger players in the cannabis space, including multi-state operator AYR Wellness (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>).&nbsp;
&#8220;We were ranked first or second nationally, even though we were only in <a href="https://www.benzinga.com/topic/massachusetts-cannabis">Massachusetts</a>,&#8221; Kristin said. &#8220;AYR had the largest footprint of the companies that approached us, and we saw it as an opportunity to scale.&#8221;
Since the acquisition, Kristin has remained with the company, learning from the broader operations at AYR. &#8220;I've learned so much about different parts of the business that I wouldn't have had the chance to before. It's been an exciting journey.&#8221;
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/40972472/x-rays-microwaves-and-now-what-this-company-freezes-weed-at-320-f-to-kill-mold-and-save-a-ton"> X-Rays, Microwaves And Now What? This Company Freezes Weed At -320°F To Kill Mold And Save A Ton</a>
<h3 class="wp-block-heading">Passion, Innovation, Persistence</h3>
For other cannabis entrepreneurs looking to make their mark in an increasingly competitive market, Kristin offers some valuable advice. &#8220;Be an expert in what you do and approach it with passion. Right now, MSOs [multi-state operators] aren't looking for the same old thing. They want better products or new ways for people to enjoy cannabis.&#8221;
Today, LEVIA continues to lead in the cannabis beverage market, with plans to expand beyond Massachusetts.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="703" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164843/Levia-x3-703x1024.jpg" alt="" class="wp-image-601650" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164843/Levia-x3-703x1024.jpg 703w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164843/Levia-x3-206x300.jpg 206w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17164843/Levia-x3.jpg 741w" sizes="(max-width: 703px) 100vw, 703px" /><figcaption class="wp-element-caption">Courtesy of LEVIA. </figcaption></figure>
The brand's popular tinctures have already made their way to states like Florida and Nevada, and Kristin is particularly excited about entering New Jersey. &#8220;There's a camaraderie between Massachusetts and New Jersey, and I'm most looking forward to getting our drinks there next.&#8221;
As for the immediate future, LEVIA has launched its Blood Orange seltzer, a limited-edition flavor timed for Halloween. &#8220;We wanted to do something seasonal, and people love the orange flavor. It&#8217;s been a hit already,&#8221; Kristin said.
Read Next:<a href="https://www.benzinga.com/general/biotech/24/09/40754415/transforming-a-5-000-year-old-craft-how-weed-companies-use-data-to-make-hash-without-losing-its-a"> Transforming A 5,000-Year-Old Craft: How Weed Companies Use Data To Make Hash Without Losing Its Art</a>

Biotech

Cannabis

Market Summary

News

Contracts

Retail Sales

Management

Success Stories

Startups

Exclusives

Markets

Interview

AYRWF

Sold Out Before Hitting Shelves: Why Did AYR Wellness Snatch Up This Local Cannabis Brand?

Ryan Routh, charged with the attempted assassination of former President Donald Trump, has requested the recusal of U.S. District Judge Aileen Cannon from his case, citing potential bias.
What Happened: Routh&#8217;s legal team submitted a request on Thursday for Judge Cannon to step down from the case. They argued that the &#8220;unprecedented circumstances&#8221; surrounding the case could lead to a perception of partiality, given that Trump, who appointed Cannon and has publicly praised her, is the alleged victim, <a href="https://thehill.com/regulation/court-battles/4940160-ryan-routh-trump-assassination-cannon-recuse/">reported</a> The Hill.
Trump, currently running as the Republican presidential candidate against Vice President Kamala Harris, has frequently commended Cannon for her rulings in his case. Routh&#8217;s lawyers contend that if Trump were to be re-elected, he could potentially nominate Cannon for a higher federal judgeship, thereby creating a conflict of interest.
&#8220;By repeatedly and publicly praising this Court by name for its rulings in his case, Mr. Trump has arguably bolstered the perception that the Court is partial in his favor,&#8221; wrote the attorneys of Routh.
Interestingly, Cannon is presiding over both Routh&#8217;s criminal prosecution and the criminal prosecution of Trump by special counsel Jack Smith for allegedly retaining classified documents unlawfully. Cannon dismissed Trump&#8217;s charges in July, a decision Smith is now appealing.
Routh&#8217;s attorneys maintain that federal law necessitates Cannon&#8217;s recusal, given Trump&#8217;s public endorsement of her. Federal prosecutors are currently reviewing the request.
Routh is facing five criminal charges, including the attempted assassination of a major presidential candidate. If found guilty, he could be sentenced to life imprisonment.
See Also: <a href="https://www.benzinga.com/news/24/10/41348822/mark-cuban-says-he-knows-what-trump-wants-to-achieve-with-tariffs-but-the-ex-president-has-no-idea-w?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Says He Knows What Trump Wants To Achieve With Tariffs But The Ex-President Has No Idea What It Takes To Do It — &#8216;That&#8217;s How Crazy His Approach Is&#8217;</a>
Why It Matters: Routh was charged with two federal gun-related offenses in connection with his <a href="https://www.benzinga.com/general/politics/24/09/40882524/man-accused-in-trump-assassination-attempt-could-face-15-years-for-federal-gun-crimes-whats-next">attempted assassination of Trump</a>, marking the second attempt on the former president&#8217;s life ahead of the 2024 election.
Trump was escorted to safety <a href="https://www.benzinga.com/24/09/40869836/donald-trump-safe-and-unharmed-after-shooting-incident-at-florida-golf-club">following a shooting incident</a> at his Florida golf club, as reported by <a href="https://www.benzinga.com/24/09/40869836/donald-trump-safe-and-unharmed-after-shooting-incident-at-florida-golf-club">Benzinga</a>. 
This month, Another man was <a href="https://www.benzinga.com/news/24/10/41306168/man-held-with-loaded-weapon-ne">arrested with loaded firearms</a> near a rally site for Trump in California, possibly preventing a third assassination attempt.
In July, a shooter at a Donald Trump rally in Butler, Pennsylvania was killed, and one attendee died. Trump was led offstage by Secret Service agents while <a href="https://www.benzinga.com/general/politics/24/07/39761947/gunman-dead-trump-rally-attendee-killed-says-local-da-former-president-comes-under-fire-in-penns">bleeding from his ear.</a>
Image via Flickr
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Trump Assasination Suspect Wants Judge Aileen Cannon To Recuse Herself: The Ex-President Has 'Bolstered The Perception That The Court Is Partial In His Favor'

BIOR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Kintara Therapeutics, Inc. - Common Stock

KTRA

SDOT

SANW

A close head-to-head battle between Donald Trump and Vice President Kamala Harris is expected in polls for the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
Betting prediction markets paint a different picture with one candidate jumping out to a sizable lead. Here's the latest.
What Happened: Prediction markets Polymarket and Kalshi are among the companies taking election betting by storm and often showing wide swings on the leading candidate, something that has drawn red flags<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41363075/26m-bet-on-trumps-election-victory-fuels-speculation-of-coordinated-activity-on-polymarket"> in recent weeks.</a>
Polymarket witnessed a wide swing in Trump's favor, which comes with several large wagers placed on him, which could sway the percentage chance he has of winning and not be indicative of how people will vote or who the majority of people think will win.
On Kalshi, Trump is also seeing his lead grow, with the prediction market for the 2024 presidential election winner showing a 58% chance for Trump and 42% chance for Harris on Thursday, hitting a record-high 16-point lead for the former president.
At the time of writing, the market shows Trump at 57% and Harris at 43% with over $22.9 million in wagers. Polymarket shows Trump with a 61% chance of winning and Harris with a 39% chance of winning with a $1.9 billion bet.
Kalshi recently <a href="https://www.benzinga.com/news/24/09/40760283/betting-on-u-s-elections-federal-judges-decision-greenlights-political-wagers" target="_blank" rel="noreferrer noopener">resumed accepting bets&nbsp;</a>on the 2024 election after a federal appeals court lifted a prior ban that came as the Commodity Futures Trading Commission (CFTC) contested the markets.
The company calls itself the only place to legally bet on the election in the U.S., with other prediction markets and sportsbooks not allowed to legally accept wagers in the country.
While prediction markets show Trump as the overall leader, the key markets could be on the individual swing states that could determine the election. 
Here are the current <a href="https://kalshi.com/live/swing-states">odds </a>on Kalshi, with electoral college votes for each state in parentheses:
<ul>
<li>Arizona (11): Trump 64%, Harris 36%</li>
<li>Georgia (16): Trump 60%, Harris 40%</li>
<li>Michigan (15): Harris 51%, Trump 49%</li>
<li>Nevada (6): Harris 52%, Trump 48%</li>
<li>North Carolina (16): Trump 58%, Harris 42%</li>
<li>Pennsylvania (19): Trump 54%, Harris 46%</li>
<li>Wisconsin (10): Trump 52%, Harris 48%</li>
</ul>
The current odds show Harris winning two states and getting 21 electoral college votes from the seven key states and Trump winning five states and getting 72 electoral college votes from the swing states.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent101724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: On Polymarket, users can deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network, or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). In each betting market, the winning options pays out at $1.
Polymarket could show results that skew to a more international audience, while Kalshi could provide a better look at who American voters think will win.
Both prediction markets differ from national election polls for the overall winner, where Harris is often the winner. Sportsbooks show Trump as<a href="https://www.benzinga.com/general/sports-betting/24/10/41347270/trump-vs-harris-2024-election-polls-sportsbooks-betting-odds-show-different-winners-for-20"> the slight favorite,</a> but much closer than the prediction markets.
A<a href="https://www.benzinga.com/general/politics/24/10/41283673/trump-vs-harris-2024-election-swing-state-poll-too-close-to-call-but-this-candidate-leads"> recent Emerson College poll </a>of voters in the <a href="https://www.benzinga.com/topic/swing-states">seven key swing states </a>showed a similar result to the Kalshi markets above.
<ul>
<li>Arizona: Trump 49%, Harris 47%</li>
<li>Georgia: Trump 49%, Harris 48%</li>
<li>Michigan: Trump 49%, Harris 49%</li>
<li>Nevada: Harris 48%, Trump 47%</li>
<li>North Carolina: Trump 49%, Harris 48%</li>
<li>Pennsylvania: Trump 49%, Harris 48%</li>
<li>Wisconsin: Trump 49%, Harris 49%</li>
</ul>
That poll showed Trump leading in four states, Harris leading in one and the candidates tied in two states. The percentages were much closer than the prediction markets though.
The seven swing states in question together represent 93 electoral votes in the 2024 election. Six of the seven states were won by President Joe Biden in the 2020 election with Trump winning North Carolina. Several of the states were flipped from Trump's win in the 2016 election.
An X account shared an update from election predictor Nate Silver saying Trump has a 50% chance of winning the 2024 election. The model jumps to 93% chance if Trump wins Pennsylvania.
The tweet prompted a response from Tesla CEO Elon Musk who has publicly supported Trump and is now campaigning for him.
"That's why I'm in Pennsylvania," Musk <a href="https://x.com/elonmusk/status/1847000395912302630">said</a>.
Musk <a href="https://x.com/elonmusk/status/1846996928451826093">said </a>"making progress" earlier Thursday when sharing the Kalshi market that showed Trump with an all-time high lead in the prediction market.
The new prediction of the importance of Pennsylvania and its 19 electoral votes and Trump's growing lead in the state could illustrate why the overall presidential race is close.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/24/10/41302431/elon-musk-to-end-year-as-richest-man-in-the-world-prediction-market-says-yes-higher-chance-than-l">Elon Musk To End Year As Richest Man In The World? Prediction Market Says Yes, Higher Chance Than Larry Ellison Or Jensen Huang</a></li>
</ul>
Photo: Shutterstock

$ETH

$MATIC

$USDC

USDC

Trump Vs. Harris Swing State Battle: Musk Says 'That's Why I'm In Pennsylvania' With Kalshi Prediction Market Results On Display

Allstate Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) reported $630 million in catastrophe losses related to Hurricane Helene alone. The company reported total estimated catastrophe losses of $889 million for September, more than twice the amount reported <a href="https://www.benzinga.com/pressreleases/24/10/b41378242/allstate-announces-september-and-third-quarter-2024-catastrophe-losses-run-off-reserve-review-and-">for the same month last year.&nbsp;</a>
What Happened: The impact of Hurricane Helene has led to a substantial increase in Allstate&#8217;s losses for the third quarter of 2024 which the company reported as $1.7 billion, up from $1.18 billion in the same quarter in 2023. 
Other insurance companies affected by the recent hurricanes include Progressive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>), which <a href="https://www.benzinga.com/pressreleases/24/10/g41329804/progressive-reports-september-2024-results">recorded</a> $563 million in catastrophe in September as a result of Hurricane Helene. Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) reported catastrophe losses of $939 million for the third quarter of 2024 due to Hurricane Helene, an increase of $89 million compared to the same period last year.
Read Next: <a href="https://www.benzinga.com/news/24/10/41385546/ftc-click-to-cancel-rule-makes-it-easy-to-end-subscriptions-what-it-means-for-netflix-planet-fitness">FTC &#8216;Click-To-Cancel&#8217; Rule Makes It Easy To End Subscriptions: What It Means For Netflix, Planet Fitness And More</a>
Moody's Risk Management Solutions, or RMS, said<a href="https://www.benzinga.com/news/24/10/41321615/hurricanes-helene-milton-insurance-losses-spike-to-55b-moodys"> it expects</a> combined total insured losses from Hurricane Helene and Hurricane Milton to range between $35 billion and $55 billion.
According to <a href="https://www.insurtechinsights.com/hurricanes-helene-and-milton-floridas-insurance-market-on-the-brink/">a report</a> from Insurtech Insights, Hurricanes Helene and Milton contributed to total losses for Florida insurers of more than $100 billion for the fifth consecutive year, comparable to the losses from Hurricane Katrina in 2005.&nbsp;
Why It Matters: Citizens, Florida's state-backed insurer of last resort, has seen a surge in policyholders in recent years, especially after recent destructive hurricanes. 
The rapid influx raises serious concerns about its financial stability as it has experienced massive underwriting losses, amounting to hundreds of millions of dollars. Citizens estimates it is currently at a 38% rate inadequate, meaning it needs a 38% rate increase to be solvent. However, Florida law caps its annual rate increases at 10%
Citizens is transferring more than 648,000 policies to private insurers, per<a href="https://www.clickorlando.com/news/local/2024/10/04/what-citizens-insurance-depopulation-means-for-florida-homeowners/"> Click Orlando</a>. These companies are also experiencing <a href="https://www.benzinga.com/markets/equities/24/10/41240852/back-to-back-hurricanes-batter-floridas-insurance-market-stocks-to-watch">financial strain</a> due to increased claims, likely leading to higher premiums and reduced coverage availability.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41346351/cybersecurity-firm-warns-of-threats-to-2024-presidential-election-integrity">Cybersecurity Firm Warns Of Threats To 2024 Presidential Election Integrity</a>&nbsp;</li>
</ul>
Photo: wurliburli from Pixabay

Movers

Insurance

Allstate Records $630M In Losses From Hurricane Helene, Other Insurers Report Significant Losses As Damage Mounts

Merck also announced data from a planned interim analysis of the MK-1654-007 trial, a Phase 3 trial evaluating the safety and efficacy of clesrovimab versus palivizumab in infants and children at increased risk for severe RSV disease.
The primary endpoint of the study is the safety and tolerability of clesrovimab in infants entering their first RSV season. Interim results showed clesrovimab had a comparable safety profile to palivizumab, and no drug-related serious AEs were reported to date.
Incidence rates of RSV-associated MALRI requiring &ge; 1 indicator of LRI or severity and RSV-associated hospitalizations (secondary endpoints) were also comparable between clesrovimab (3.6%&nbsp;and&nbsp;1.3%, respectively) and palivizumab (3.0%&nbsp;and&nbsp;1.5%, respectively) through Day 150 (5 months).

Merck Reports Data From Planned Interim Analysis Of MK-1654-007 Trial; Interim Results Showed Clesrovimab Had Comparable Safety Profile To Palivizumab And No Drug-Related Serious Adverse Events Were Reported To Date

In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than&nbsp;84%&nbsp;and&nbsp;90%, respectively, through 5 months.
Clesrovimab has the potential to become the first and only approved immunization designed to protect infants with the same single dose regardless of weight for the duration of their first RSV season.

Merck Reports Results From Phase 2b/3 Clinical Trial Evaluating Clesrovimab; Results From MK-1654-004 Trial Met All Prespecified Endpoints

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has dominated the electric vehicle sector for years, but is seeing its global market share under pressure in China and other territories with Chinese EV companies <a href="https://www.benzinga.com/markets/equities/24/09/40669363/teslas-china-rivals-report-steady-august-sales-performance-amid-intense-price-competition-what-i">launching low-cost models.</a>
What Happened: Tesla and the <a href="https://www.benzinga.com/electric-vehicles">electric vehicle sector </a>could have another rival soon with Chinese company Skywell unveiling new electric vehicles at the 2024 Paris Auto Show this week.
Skywell may not be a household name in the U.S. yet, but there's a chance that consumers are familiar with the company's Skyworth affordable televisions that are sold in America by Walmart and Amazon.
Skywell unveiled the Q hatchback electric vehicle at the auto show, as <a href="https://electrek.co/2024/10/17/this-maker-of-cheap-tvs-just-launched-a-solid-looking-ev/">reported </a>by Electrek. The vehicle could compete against other similar electric vehicle offerings like the VW ID.3, Cupra Born and BYD Dolphin, according to the report.
The Q is expected to go on sale in 2025 in Europe and be "competitively priced." While not all details have been released, the report notes that a larger battery option available could provide up to 300 miles of range and the 0-60mph time is quicker than the strong-selling BYD Dolphin.
The company best known for its televisions and electronics previously launched the BE11 in the U.K. and sold electric vehicles in Israel previously, Electrek reported.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: While it's early into the Q launch phase, the Electrek report said the vehicle looks to be a potential contender in the electric vehicle space.
While a transition from making affordable televisions to affordable electric vehicles may sound like a stretch, many technology companies have evolved from their early roots.
Electrek shares the examples of BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) previously making mobile phones before cars, and Volvo owner Geely making refrigerator parts before vehicles. Let's not forget that Nintendo got its start as a playing cards company before getting into video games.
How the company got its start shouldn&#8217;t be the concern here for Tesla and other EV makers, the major concern should be the potential lower price point. 
The Skywell vehicle might not hit the market and might never be available for sale in the U.S. The potential release and focus on a lower price point will likely put the potential vehicle in competition with BYD and other Chinese electric vehicle companies.
These Chinese companies continue to put pressure on Tesla's global market share. While Tesla has been competitive on pricing for years thanks to its vertical integration, the company is getting beat in price by several models in the competitive battle for market share and units sold.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41027049/tesla-returns-to-paris-motor-show-for-first-time-in-6-years-cybertruck-to-be-featured-will-elon-musk">Tesla Returns To Paris Motor Show For First Time In 6 Years: Cybertruck To Be Featured, Will Elon Musk Present?</a></li>
</ul>
Photos: Unsplash/Pixabay

Global

BYDDY

TSLA

Tesla Has A New Chinese Electric Vehicle Competitor: How A Company That Used To Sell Cheap TVs Is Entering EV Race

CMCSA

Comcast Installs Its First Flagship Lift Zone In Partnership With Inspiredu In Atlanta, Georgia

The Palliser Block consists of oil and gas wells, surface facilities, a pipeline network and certain oil and gas development rights. The transaction, which is subject to regulatory approval and other customary closing conditions, is expected to close late in the&nbsp;fourth quarter&nbsp;of 2024.

Asset Sales

SLB Agrees To Sell Its Interests In The Palliser Block Located In Alberta, Canada; No Terms Disclosed

&quot;The transition to a facility with competitive power costs, reliable uptime, and continued upgrades to our mining fleet ensures that we are well-positioned for profitability and growth through 2025,&quot; the company said.

Guidance

Sphere 3D Anticipates Strong Bitcoin Market And Remain Focused On Executing Strategic Plan Looking Ahead To Q4 And Into 2025

Mining production decreased in September as the company focused on its long-term strategic goal of transitioning to lower-cost hosting sites. The decrease reflects significant changes at one colocation site, where the hosting provider bought out the company&#39;s contract.
This buyout has strengthened the company&#39;s balance sheet by increasing cash reserves and lowering overall cost of mining. The company is currently evaluating miners from this site and is actively exploring more affordable hosting options.
In line with this strategic shift, the company has recently added 0.21 EH/s of higher-efficiency machines to its fleet. These machines are expected to go live in October, in addition to a total of 1,000 Bitmain S21 units scheduled for energization by Q4 2024 and another 1,000 Bitmain S21s in Q1 2025.

Sphere 3D Reports 9.2 Bitcoin Mined In September 2024, Down From 63.6 Prior Year

Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) reported quarterly earnings of $1.80 per share which missed the analyst consensus estimate of $1.89 by 4.76 percent. This is a 8.63 percent decrease over earnings of $1.97 per share from the same period last year. The company reported quarterly sales of $823.10 million which beat the analyst consensus estimate of $808.19 million by 1.84 percent. This is a 14.93 percent increase over sales of $716.20 million the same period last year.

Earnings

UPDATE: Western Alliance Q3 GAAP EPS $1.80 Misses $1.89 Estimate, Sales $823.10M Beat $808.19M Estimate

To cure defaults, maintain appropriate liquidity and support the Company&#39;s transformation initiatives, Comtech entered into a new&nbsp;$25.0 million&nbsp;subordinated unsecured term loan facility with the existing holders of the Company&#39;s convertible preferred stock.
Within the terms of the amended credit facility, this new subordinated unsecured term loan allows the Company to maintain a consistent level of borrowing capacity.

CMTL

Comtech Reports Delay In Filing Annual Report; Expects Reporting Significantly Lower-Than-Expected Performance, Primarily In Its S&S Segment, In Q4

In connection with the Board&#39;s transformative strategy, the Company has undertaken a detailed evaluation of its S&amp;S portfolio to identify opportunities to divest, separate and/or rationalize businesses or facilities that are not core to Comtech&#39;s go-forward focus.
Consistent with this effort, in its fourth fiscal quarter, Comtech made the decision to exit its subsidiary operations in Basingstoke, United Kingdom.
Taking into consideration the significant ongoing investment as well as unfavorable contract terms on prospective antenna sales, the Board concluded the U.K. business would not generate an attractive return on invested capital and made the decision to exit these operations. After anticipated restructuring charges associated with the exit of the Basingstoke operations, Comtech expects to realize approximately&nbsp;$10 million&nbsp;of annual cash savings.

Comtech Says Working With Independent Advisors To Identify Opportunities To Align Cost Structure; Expects Near-term Restructuring Charges

Comtech Discloses Strategic Alternatives Process For Terrestrial & Wireless Networks Segment; Amends Credit Facility

Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) has outperformed the market over the past 5 years by 2.02% on an annualized basis producing an average annual return of 16.28%. Currently, Brinker International has a market capitalization of $4.00 billion. 
Buying $100 In EAT: If an investor had bought $100 of EAT stock 5 years ago, it would be worth $217.01 today based on a price of $89.30 for EAT at the time of writing.
<h3>Brinker International's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729200662_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Brinker International 5 Years Ago Would Be Worth Today

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
When does a growth stock become one of the top <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> to avoid?



It sounds like the beginning of a riddle or a bad joke, but the answer is obvious &ndash; it&rsquo;s when the stock is deceptive and tricks you into believing that it can be a good buy. You look at the Portfolio Grader and get interested because a stock has a good grade specifically for growth, but then realize that it still has an &ldquo;F&rdquo; rating overall.



How can that happen?



The Portfolio Grader rates stocks based on earnings history, growth, analyst sentiment and momentum. The growth grade in particular is a popular metric for finding growth stocks to avoid.



But it&rsquo;s also important to see why a company is getting a good growth grade. Because sometimes, looking at a single factor like growth can be misleading and can&rsquo;t make up for the company&rsquo;s deficiencies in other areas.



Today, we&rsquo;re going to look at several companies that have good growth grades, and we&rsquo;ll investigate why that&rsquo;s happening in each case. But then we&rsquo;ll pull back the curtain, look at the fuller picture, and explore why these growth stocks to avoid are still getting &ldquo;F&rdquo; grades overall.



In the end, an exercise like this is a good reminder to not rely on any one metric when considering your stock portfolio. Growth is highly desirable, but the growth stocks to avoid on this list can easily drag your portfolio into the gutter.



<h2>Virgin Galactic (SPCE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/spce1600-300x169.jpg" alt="Virgin Galactic (SPCE) billboard on the New York Stock Exchange, across from the Fearless Girl statue. aerospace stocks"><div>Source: Tun Pichitanon / Shutterstock.com</div></div>It makes sense to jump right into one of the growth stocks to avoid that&rsquo;s been a huge disappointment &ndash; and has cost plenty of investors a lot of money along the way. 



Virgin Galactic (NYSE:<a href="https://investorplace.com/stock-quotes/spce-stock-quote/">SPCE</a>) made its name in the billionaire space race as founder Richard Branson competed with SpaceX and Blue Orgin to see which would be the first to make it into space with a civilian crew. 



You may remember that Virgin Galactic won that race, as it shot Branson into suborbital flight just a few days before Jeff Bezos did the same on a Blue Orgin rocket.



But honestly, that&rsquo;s the high point for this company. Space tourism doesn&rsquo;t feel any closer today than it did several years ago, and few people have the several hundred thousand dollars it takes to make the trip, even if the flights become a reality.



Virgin Galactic has burned through more than $1 billion in the last two years and rewarded investors with a 93% fall in stock price. SPCE recently completed a <a href="https://investorplace.com/2024/06/will-a-1-for-20-reverse-split-save-virgin-galactic-spce-stock/">1-for-20 reverse stock split</a> to push the price back over the Nasdaq threshold and maintain listing compliance, but the reality is that this is a bad stock and a weak company.



SPCE stock shows an &ldquo;A&rdquo; rating for growth in the Portfolio Grader because its revenue was up 410% in the last quarter. But sales of only $1.99 million show that people aren&rsquo;t lining up to ride a <a href="https://seekingalpha.com/article/4690417-virgin-galactic-holdings-inc-spce-q1-2024-earnings-call-transcript?source=content_type%3Areact%7Csection%3ATranscripts%7Csection_asset%3ATranscripts%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A2">Delta rocket</a> into space as early as 2026, which is the company&rsquo;s latest projections.



SPCE stock gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Helius Medical Technologies (HSDT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/tech1600a-300x169.jpg" alt="Image of hand touching globe with a city in the background, implying connectivity"><div>Source: Shutterstock</div></div>Helius Medical Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) is a neurotech company headquartered in eastern Pennsylvania. The company makes medical devices that help people with balance and gait issues without getting a neurological implant. It is also one of the growth stocks to avoid in the space.



The company&rsquo;s devices improve the brain&rsquo;s ability to compensate for deficiencies and rehabilitate lost brain function. For instance, its Portable Neuromodulation Stimulator stimulates the brain through nerves in the tongue. 



It&rsquo;s being used as a short-term treatment to help people with multiple sclerosis symptoms. But it&rsquo;s an expensive device, priced at more than $23,000.



The company saw <a href="https://ir.heliusmedical.com/news-releases/news-release-details/helius-medical-technologies-inc-reports-first-quarter-2024">revenue grow</a> in the first quarter, giving it a decent growth grade in the Portfolio Grader. But we&rsquo;re still not looking at a lot of money. Revenue in the first quarter was $135,000, versus $111,000 in the same quarter a year ago.



It posted a net loss of $2.5 million, the same as a year ago. The earnings per share loss of $3.08 was better than the loss of $4.22 per share from Q1 2023.



HSDT stock is down 87% this year. It has an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>InMed Pharmaceuticals (INM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-1-1-300x169.jpg" alt="cannabis stocks"><div>Source: Shutterstock</div></div>InMed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/inm-stock-quote/">INM</a>) is a Canadian company that is a clinical-stage pharmaceutical company that&rsquo;s working to develop cannabis-infused treatments for Alzheimer&rsquo;s disease, vision and skin conditions.



The company is attempting to develop an effective pipeline of drug candidates targeting CB1 and CB2 receptors. 



Its attempt to develop an anti-itch skin cream is in Phase 2 testing, and it is seeking a partnership to help it develop the product. Its other pipeline candidates for Alzheimer&rsquo;s and dry age-related macular degeneration are in preclinical trials.



Developing new therapies is an expensive undertaking and a challenge for investors because the company has to spend a lot of cash on research and development without seeing income for years, if ever.



For the third fiscal quarter of 2024 (ending March 31), InMed reported a net loss of $5.7 million. The company saw sales of $1.1 million, up slightly from a year ago, and a gross profit of $289,000, which was better than its profit of $192,511 in the same quarter a year ago.



The profit increase helps InMed&rsquo;s growth grade in the Portfolio Grader. Still, the company also acknowledges that it has money only to finance research and development into the fourth calendar quarter of 2024. That is a worrisome disclosure.



INM stock gets a &ldquo;B&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 36% this year.



<h2>P3 Health Partners (PIII)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a-300x169.jpg" alt="stethoscope on a stock chart representing healthcare stocks to buy. Healthcare Stocks"><div>Source: Shutterstock</div></div>P3 Health Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/piii-stock-quote/">PIII</a>) is a health management company that supports providers with administrative services and coordination for their Medicare Advantage patients.



The company currently operates in Arizona, Oregon, Nevada, Florida and California, with a network of more than 2,900 primary care providers.



It recently announced raising <a href="https://ir.p3hp.org/news-events/press-releases/detail/106/p3-health-partners-inc-announces-approximately-42-2">$42.2 million</a> through the sale of 67.4 million units of stock with institutional investors, valued at just over 62 cents per share. That will give the company an infusion of cash to operate, but it also serves to dilute the share base.



First-quarter financial results included $388.5 million in revenue, up 29% from a year ago. But gross profits fell from $16.5 million to $6.4 million, and the company reported a net loss of $49.6 million.



PIII is among the growth stocks to avoid in part because it is down 62% this year. It gets an &ldquo;A&rdquo; rating for growth, but still has an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Sunshine Biopharma (SBFM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) is a Florida-based biopharma company developing potential treatments in oncology and antivirals.



Thanks to its ownership of a Canadian pharmacy, Nora Pharma, which distributes generic medications, Sunshine was able to show <a href="https://sunshinebiopharma.com/wp-content/uploads/20240521_SBFM-Press-Release-Reports-Q1_2024_.pdf">sales</a> of $7.5 million in the first quarter, a gain from $4.8 million a year ago. That gives it a solid grade for growth in the Portfolio Grader.



However, Sunshine is a long path to ever bringing its own drugs to market, and that&rsquo;s where the real money is made. Sunshine is currently testing a Covid-19 treatment in mice at the University of Arizona in hopes of developing a treatment for patients who cannot use Paxlovid, Molnupiravir or Remdisivir.



It has a second drug candidate, to treat cancer, ready for testing on mice as well. However, the company&rsquo;s third drug candidate, also a cancer drug, is on hold after lab tests did not yield a favorable result.



The Nora Pharma sales weren&rsquo;t enough to help Sunshine generate a profit for the quarter, either. It posted a net loss of $1.2 million versus a loss of $1.7 million in the first quarter of 2023.



SBFM stock is down 98% this year. It gets an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>MicroVision (MVIS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/mvis1600-300x169.png" alt="Autonomous Self Driving Car Moving Through highway - Animated Scanning Visualization Concept of Artificial Intelligence Digitalizes and Analyzes Road Using Lidar. MVIS stock"><div>Source: aslysun / Shutterstock.com</div></div>With more vehicles on the road these days than ever, the advances in driver-assisted technology are pretty interesting. MicroVision (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvis-stock-quote/">MVIS</a>) makes automotive lidar sensors to help driver-assistance systems and autonomous vehicles function.



The company&rsquo;s sensors are also used in industrial, smart infrastructure and robotics.



It gets a good grade for growth in the Portfolio Grader because the company increased its revenue in the first quarter, bringing in $956,000 versus $782,000 in the first quarter of 2023. That&rsquo;s a healthy percentage increase that helps give it an &ldquo;A&rdquo; grade for growth.



But then look closer. MicroVision lost <a href="https://ir.microvision.com/news/press-releases/detail/402/microvision-announces-first-quarter-2024-results">$26.3 million in the quarter</a>, versus a loss of $19 million in the same quarter a year ago. When you&rsquo;re losing that much money, an $174,000 increase in revenue doesn&rsquo;t help that much.



MVIS stock is down 59% this year. Despite its &ldquo;A&rdquo; grade for growth, MicroVision gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Predictive Oncology (POAI)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1-300x169.jpg" alt="A concept image representing AI (artificial intelligence)."></a>Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) is working to harness the power of artificial intelligence to help bring drugs to market. The company believes that AI can help reduce the time it takes to successfully test and manufacture a drug, and is working specifically on cancer therapies.



The company has a biobank of&nbsp;<a href="https://predictive-oncology.com/biobankai/">150,000 tumor tissue samples</a>&nbsp;and uses machine learning to help it test and discover successful molecules. It also uses AI for drug development and for clinical trials.



And it saw an uptick in revenue in the first quarter, bringing in $419,000 versus $239,000 in the first quarter of 2023.



But the company also posted a loss of $4.2 million and $1.04 per share, versus a loss of $3.4 million and 86 cents per share in the same quarter a year ago.



That&rsquo;s why POAI stock is getting an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 67% this year.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-f-rated-growth-stocks-to-avoid-right-now-june-2024/">7 F-Rated Growth Stocks to Avoid Right Now: June 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 F-Rated Growth Stocks to Avoid Right Now: June 2024

P3 Health Partners GAAP EPS of -$0.15 misses by $0.05, revenue of $379.2M misses by $2.9M

P3 Health Partners Inc. (PIII) Q2 2024 Earnings Call Transcript

BTIG analyst David Larsen maintained a Hold rating on P3 Health Partners (PIII – Research Report) today. The company's shares opened today at $0.60...

BTIG Reaffirms Their Hold Rating on P3 Health Partners (PIII)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Siemens Healthineers AG (SEMHF – Research Report) and P3 Health P...

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF) and P3 Health Partners (PIII)

P3 Health Partners appoints Leif Pedersen as CFO

P3 Health Partners (PIII) has provided an announcement. Leif Pedersen has been appointed as the new Chief Financial Officer of P3 Health Partners I...

P3 Health Partners Announces New CFO and Compensation Details

Lake Street Reaffirms Their Buy Rating on P3 Health Partners (PIII)

P3 Health Partners (PIII) Gets a Buy from Lake Street

Warning: PIII is at high risk of performing badly

HSDT

MVIS

PIII

PIIIW

POAI

SBFM

SEMHF

SPCE

Press Releases

P3 Health Partners Announces First Quarter 2024 Results

P3 Health Partners Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

P3 Health Partners Inc. Announces Approximately $42.2 Million Private Placement

P3 Health Partners to Present at Upcoming Investor Conferences

P3 Health Partners Forms Strategic Partnership with Innovaccer to Drive Value-Based Care and Patient Experience

P3 Health Partners Schedules Second Quarter 2024 Earnings Release and Conference Call

P3 Health Partners Announces Second Quarter 2024 Results

P3 Health Partners Names Leif Pedersen New Chief Financial Officer

P3 Health Partners to Present at the LD Micro Main Event XVII

Accolade

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

ATI Physical Therapy, Inc. Class A Common Stock

ATI Physical Therapy

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

CareMax

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Kindly MD

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Nutex Health

Ontrak

Performant Financial Corporation - Common Stock

Performant Finl

Psychemedics

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

Comments

P3 Health Partners

Noticias

Últimas noticias sobre P3 Health Partners (NASDAQ:PIII) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL